The estimated Net Worth of Sarah Cavanaugh is at least 1.26 百万$ dollars as of 30 May 2024. Ms. Cavanaugh owns over 20,853 units of Celldex Therapeutics stock worth over 945,769$ and over the last 7 years she sold CLDX stock worth over 316,793$. In addition, she makes 0$ as Senior Vice President - Corporate Affairs and Administration at Celldex Therapeutics.
Sarah has made over 5 trades of the Celldex Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 20,853 units of CLDX stock worth 120,947$ on 30 May 2024.
The largest trade she's ever made was exercising 32,667 units of Celldex Therapeutics stock on 17 August 2022 worth over 99,308$. On average, Sarah trades about 5,324 units every 112 days since 2017. As of 30 May 2024 she still owns at least 22,713 units of Celldex Therapeutics stock.
You can see the complete history of Ms. Cavanaugh stock trades at the bottom of the page.
Sarah Cavanaugh serves as Senior Vice President - Corporate Affairs and Administration of the Company. Ms. Cavanaugh served as Vice President, Investor Relations and Corporate Communications of Celldex from August 2012 to June 2017. Prior to Celldex, she served from 2007 to 2012 as a Vice President at MacDougall Biomedical Communications, a strategic communications and investor relations firm for the life sciences industry. Ms. Cavanaugh previously served as Director of Corporate Communications for Point Therapeutics, Inc., an oncology-focused biotech company, and Director of Corporate Communications for Fallon Community Health Plan, a leading Massachusetts managed care organization. She began her health care career at the American Cancer Society, holding various positions prior to completing her tenure there as Division Communications and Marketing Director for the Mid-South Division. Ms. Cavanaugh received her B.A. from the University of New Hampshire.
Sarah Cavanaugh is 45, she's been the Senior Vice President - Corporate Affairs and Administration of Celldex Therapeutics since 2018. There are 24 older and no younger executives at Celldex Therapeutics. The oldest executive at Celldex Therapeutics Inc. is Herbert Conrad, 87, who is the Independent Director.
Sarah's mailing address filed with the SEC is C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827.
Over the last 16 years, insiders at Celldex Therapeutics have traded over 19,527,314$ worth of Celldex Therapeutics stock and bought 273,450 units worth 1,157,166$ . The most active insiders traders include Rajesh B Parekh、Garry Arthur Neil、Inc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of 1,750,671$. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth 204,917$.
celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im
Celldex Therapeutics executives and other stock owners filed with the SEC include: